**MarketVIEW: Helicobacter pylori vaccines (CAT: VAMV065)**

**Product Name**: MarketVIEW: Helicobacter pylori vaccines

**Description**: Vaccine opportunity assessment

**Contents**: Executive presentation (.pdf) and forecast models (.xls)

**Therapeutic Area**: Novel vaccines

**Publication date**: December 2015

**Catalogue No**: VAMV065

**Background**

*Helicobacter pylori (H. pylori)* is one of the world’s most common infections with approximately half to two thirds of the world’s population harbouring the bacterium. *H. pylori*, which colonizes the human stomach mucosa, can cause active, chronic persistent and atrophic gastritis in adults and children. The bacterium causes more than 90% of duodenal ulcers and up to 80% of gastric cancers. Gastric cancer is the third most common cause of cancer-related deaths in the world, killing approximately 723,000 people in 2012.

*H. pylori* infection can be eradicated by use of antibiotics and proton-pump inhibitor (PPI) therapy. However, the therapy can be demanding in terms of patient compliance and its effectiveness is impacted by antibiotic resistance. Around 20% of patients fail first-line therapy and re-infection is common. Importantly, individuals are only treated on presentation with symptoms because a population wide eradication program is unfeasible. Many investigators have attempted to develop both *H. pylori* therapeutic and prophylactic vaccines with little clinical success. However, an oral urease vaccine was approved in China in 2009 after showing efficacy in Phase III studies in children.

The MarketVIEW product is a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value *H. pylori* prophylactic and therapeutic vaccines across relevant markets to 2035. Each model contains value (US$m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon the amount of countries targeted by a potential prophylactic vaccine. The therapeutic vaccine model focuses on new and ever (recurrent cases) of peptic ulcer disease.

---

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to helicobacter pylori, peptic ulcer disease, gastric cancer and related indications. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by VacZine Analytics in the field of novel bacterial vaccines has also been utilised.

PRODUCT CONTENTS:
Published December 2015 (CAT No: VAMV065)

****This product is composed of two forecast models (.xls) and a summary presentation (.pdf)

Title page
Author’s note
Contents
Executive summary
H.pylori prophylactic vaccine: revenues per scenario to 2035 ($ 000s)
H.pylori prophylactic vaccine: volumes per scenario to 2035 (000s)
H.pylori prophylactic vaccine: revenues - China and Japan ($ 000s)
H.pylori therapeutic vaccine: revenues per scenario to 2035 ($ 000s)
H.pylori therapeutic vaccine: revenues per scenario to 2035 ($ 000s)
H.pylori therapeutic vaccine: revenues to 2035 ($ 000s) new cases
H.pylori therapeutic vaccine: revenues to 2035 ($ 000s) ever cases
H.pylori: Epidemiology and general disease background
The pathogen
H.pylori: epidemiologic burden
H.pylori: epidemiologic burden (Western countries)
United States: seroprevalence of H.pylori
H.pylori: global prevalence map
H.pylori - trends in epidemiology
What is the outcome of H.pylori infection?
What is the outcome of H.pylori infection?
Natural history of H.pylori infection
H.pylori - molecular pathogenesis
H.pylori - mechanism of tumorigenesis
Diagnosis of H.pylori infection
H.pylori and gastric cancer: general background
Gastric Cancer Estimated Incidence, Worldwide in 2012: Men
Gastric cancer: incidence rates per top 20 countries, 2012
Gastric cancer: focus countries - China and Japan
Trends in incidence of stomach cancer in selected countries: age-standardised rate per 100,000, men
H.pylori and non cardia gastric cancer and CagA strains
Global distribution of cag pathogenicity island
Major outcome: peptic ulcer disease
Peptic ulcer disease and H.pylori infection

---

2 Model contents available upon application
Continued........

Diagnosis of H.pylori infection
Indications for H.pylori treatment
Treatment of H.pylori infection
First-Line Regimens for H.pylori eradication
H.pylori treatment: understanding patient flow (PUD)
H.pylori and antibiotic resistance, other factors
H.pylori and antibiotic resistance (developing world)
Economic burden of Gastrointestinal diseases
Peptic ulcer disease: pharmaceuticals market value (2017)
H.pylori eradication therapy: global market value 2005
H.pylori - other disease outcomes
H.pylori vaccine development
History of R&D approaches and current status
The medical need for a H.pylori vaccine
Notable challenges to H.pylori vaccine development
History of H.pylori vaccine development (preclinical)
Potential H.pylori vaccine antigens (preclinical studies)
H.pylori vaccines: past human studies
Clinical trials for vaccine efficacy against H.pylori: summary
H.pylori vaccine: Chinese study - Chong Qing Kang Wei (CQKW)
H.pylori vaccine (CQKW): - Phase III data
CQKW vaccine - a major advance?
CQKW vaccine: potential obstacles for Western use
CQKW vaccine - current status
H.pylori vaccines - other R&D approaches (ImevaX GmbH)
H.pylori vaccines - other R&D approaches (AMRIC - Canada)
H.pylori vaccines - other R&D approaches (EpiVax)
The cost effectiveness of a H.pylori vaccine
H.pylori vaccines: modelling commercial potential
Broad target populations for a H.pylori vaccine (PX & TX)
Drivers and resists to prophylactic vaccine (PX)
Drivers and resists to therapeutic vaccine (TX)
H.pylori vaccines: Target Product Profiles (TPPs)
Modelling methodology: prophylactic vaccine (PX)
PX vaccine: hypothetical launch sequence
PX vaccine: hypothetical launch sequence: LO scenario
PX vaccine: hypothetical launch sequence: Base scenario
PX vaccine: hypothetical launch sequence: HI scenario
PX vaccine: predicted vaccine coverage (< 1yrs)
PX vaccine: predicted vaccine coverage (preadolescence)
PX vaccine: pricing estimates - guiding assumptions
PX vaccine: pricing estimates – summary
H.pylori therapeutic vaccine (PX): vaccine positioning
Modelling methodology: therapeutic vaccine (TX)
Peptic ulcer disease patient segmentation
Modelling new PUD cases (TX vaccine)
Modelling recurrent ever cases (TX vaccine)
TX vaccine: other modelling assumptions
TX vaccine: potential upsides
Bibliography
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD $9995.00 / GBP £6665.00* (Region license)*

*Indicative rate only. Prevailing rate applied to date of transaction.
*A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009
BIBLIOGRAPHY

23. China National Cancer Institute. Western rates are estimated at ~85%
29. Manuel D et al. Decreasing prevalence combined with increasing eradication of Helicobacter pylori infection in the United States has not resulted in fewer hospital admissions for peptic ulcer disease-related complications. 2007. Aliment Pharmacol Ther 25, 1423–1427
51. Sutton P. At last, vaccine-induced protection against H. pylori. Lancet. Published Online July 1, 2015 S0140-6736(15)60579-7
60. Stomach new drug is eligible for State Technological Invention Award in the first half of this year is expected to pilot production. Chongqing News Portal. Available at: http://cq.cqnews.net/html/2014-01/10/content_29389469.htm. Accessed October 2015
62. H pylori vaccine the target of $575,000 collaboration. Available at: http://www.labcanada.com/news/h-pylori-vaccine-the-target-of-


68. Sandler RS et al. The Burden of Selected Digestive Diseases in the United States. GASTROENTEROLOGY 2002;122:1500–1511


TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within thirty days of the invoice date.
7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009